Asunercept

Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting FASLG (CD95L). Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD)[1][2][3].

Research Areas >> Cancer

Research Areas >> Inflammation/Immunology

CD95L[1][2][3].

Asunercept (APG101; 0-100 µg/mL; preincubation for 30 min) 能特异性中和重组 CD95L 的促凋亡活性[1]。 Asunercept (0.2, 2, 20 µg/mL; 72 h) 能够干扰 CD95 诱导的胶质瘤细胞的迁移/侵袭[1]。 Apoptosis Analysis[1] Cell Line: Jurkat A3 cells (APG293-induced) Concentration: 0-100 µg/mL Incubation Time: 30 min (preincubation) Result: Completely neutralized APG293-induced apoptosis. Cell Invasion Assay[1] Cell Line: U87-MG cells (CD95L knockdown; APG293-induced) Concentration: 0.2, 2, 20 µg/mL Incubation Time: 72 h Result: Blocked APG293 induced invasion of U87 cells (CD95L knockdown).

[1]. Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26(7):716-27.  

[2]. Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100.  

[3]. Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel). 2020 Dec 8;12(12):3683.